Table 2 Gene polymorphism of several human CYP epoxygenases and tumor risk
From: Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
CYP gene | Important variants | rs Number | Type of variation | Effect on enzyme activity | Cancer risk | Reference |
|---|---|---|---|---|---|---|
CYP2J2 | CYP2J2*7 | rs890293 | -50G > T(-76G > T) | Disrupted Sp1 site | – | |
CYP2C8 | CYP2C8*2 | rs11572103 | 805A > T (Ile269Phe) | Unchanged (AA) Activity reduced (Paclitaxel) | – | |
|  | CYP2C8*3 | rs11572080 rs10509681 | 416G > A (Arg139Lys) 1196A > G (Lys399Arg) | Activity reduced Activity reduced | Early breast cancer-related events (higher); Colorectal cancer risk (no association). | |
CYP2C9 | CYP2C9*2 | rs1799853 | 430C > T (Arg144Cys) | Activity reduced | Non-small cell lung cancer (lower); Head and neck squamous cell carcinoma (higher); colorectal cancer (contradictory); bladder cancer (lower); breast cancer (higher) | |
|  | CYP2C9*3 | rs1057910 | 1075A > C (Ile359Leu) | Activity reduced | Above | Above |
